GENE
Price
$0.77
Change
-$0.02 (-2.56%)
Updated
Oct 16 closing price
VMTHF
Price
$0.01
Change
-$0.63 (-98.44%)
Updated
Apr 8 closing price
Ad is loading...

GENE vs VMTHF

Header iconGENE vs VMTHF Comparison
Open Charts GENE vs VMTHFBanner chart's image
Genetic Technologies
Price$0.77
Change-$0.02 (-2.56%)
Volume$22.67K
CapitalizationN/A
VENUS MEDTECH HANGZHOU
Price$0.01
Change-$0.63 (-98.44%)
Volume$1.31K
CapitalizationN/A
GENE vs VMTHF Comparison Chart
Loading...
View a ticker or compare two or three
VS
GENE vs. VMTHF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GENE is a Hold and VMTHF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (GENE: $0.76 vs. VMTHF: $0.01)
Brand notoriety: GENE and VMTHF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GENE: 99% vs. VMTHF: 100%
Market capitalization -- GENE: $10.53M vs. VMTHF: $409.91M
GENE [@Medical Specialties] is valued at $10.53M. VMTHF’s [@Medical Specialties] market capitalization is $409.91M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GENE’s FA Score shows that 0 FA rating(s) are green whileVMTHF’s FA Score has 1 green FA rating(s).

  • GENE’s FA Score: 0 green, 5 red.
  • VMTHF’s FA Score: 1 green, 4 red.
According to our system of comparison, both GENE and VMTHF are a bad buy in the long-term.

Price Growth

GENE (@Medical Specialties) experienced а 0.00% price change this week, while VMTHF (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.22%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +1.33%.

Reported Earning Dates

GENE is expected to report earnings on Feb 28, 2024.

Industries' Descriptions

@Medical Specialties (-4.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
VMTHF($410M) has a higher market cap than GENE($10.5M). GENE YTD gains are higher at: -68.125 vs. VMTHF (-98.319). GENE has higher annual earnings (EBITDA): -12.07M vs. VMTHF (-324.03M). VMTHF has more cash in the bank: 2.96B vs. GENE (3.73M). GENE has less debt than VMTHF: GENE (382K) vs VMTHF (70.8M). VMTHF has higher revenues than GENE: VMTHF (416M) vs GENE (8.49M).
GENEVMTHFGENE / VMTHF
Capitalization10.5M410M3%
EBITDA-12.07M-324.03M4%
Gain YTD-68.125-98.31969%
P/E RatioN/AN/A-
Revenue8.49M416M2%
Total Cash3.73M2.96B0%
Total Debt382K70.8M1%
FUNDAMENTALS RATINGS
GENE: Fundamental Ratings
GENE
OUTLOOK RATING
1..100
48
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

GENE and

Correlation & Price change

A.I.dvisor tells us that GENE and VMTHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GENE and VMTHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENE
1D Price
Change %
GENE100%
N/A
VMTHF - GENE
30%
Poorly correlated
N/A
STSS - GENE
24%
Poorly correlated
-2.83%
VNRX - GENE
23%
Poorly correlated
-5.15%
BNGO - GENE
22%
Poorly correlated
-6.01%
LFWD - GENE
21%
Poorly correlated
-1.23%
More

VMTHF and

Correlation & Price change

A.I.dvisor tells us that VMTHF and GENE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VMTHF and GENE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VMTHF
1D Price
Change %
VMTHF100%
N/A
GENE - VMTHF
30%
Poorly correlated
N/A
ISPC - VMTHF
24%
Poorly correlated
+1.53%
AVCRF - VMTHF
23%
Poorly correlated
-3.89%
PRCT - VMTHF
4%
Poorly correlated
-0.96%
WRBY - VMTHF
3%
Poorly correlated
+0.45%
More